Yale Early Stage Ovarian Cancer Detection Technology Licensed By LabCorp®
Main Category: Ovarian CancerAlso Included In: Medical Devices / Diagnostics; Regulatory Affairs / Drug Approvals
Article Date: 26 Feb 2006 - 4:00 PDT
| Patient / Public: | ![]() |
4.75 (4 votes) |
| Healthcare Prof: | ![]() |
New Haven, Conn. -- Yale University Office of Cooperative Research today announced that it has granted an exclusive license agreement with Laboratory Corporation of America Holdings (LabCorp) for the commercialization of the university's blood testing technology for epithelial ovarian cancer (EOC).
In the United States, EOC is the fourth most common cancer in women, and the leading cause of gynecologic cancer death. EOC affects approximately 25,000 women each year, and more than 16,000 will die from the disease.
The Yale technology for EOC is based on a collection of known serum proteins associated with cancer biology. Each protein marker is analyzed using a routine ELISA assay, and the results evaluated using a score system.
Research, led by Gil Mor, MD, associate professor of obstetrics, gynecology and reproductive sciences at Yale, was published on the technology in 2005. Statistical analyses on preliminary sample sets of a population of 206 women, including 24 patients with early stage (I/II) EOC and 76 with later stage (III/IV) EOC, showed a higher sensitivity and specificity than currently available tests, as well as a positive predictive value. Yale expects to conduct additional clinical studies on the test technology prior to its commercial introduction by LabCorp.
"Ovarian cancer is one of the most difficult cancers to detect, especially in the earliest stages when it is more treatable," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp. "LabCorp continues to dedicate resources to identifying and commercializing tests to help discriminate earlier between disease-free and cancer patients."
###
More information about LabCorp is available online at http://www.labcorp.com/. The Yale University Office of Cooperative Research (YU-OCR) manages the intellectual assets created at Yale. Information on licensing agreements is available through ocr@yale.edu or at http://www.yale.edu/ocr/
Citation: Proc Natl Acad Sciences, 102(21) May 24, 2005.
Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
Yale University
Visit our ovarian cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/38370.php>
APA
http://www.medicalnewstoday.com/releases/38370.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




